The cost of failed first-line cancer treatment related to continued smoking in Canada

Current Oncology

View Publication Info
 
 
Field Value
 
Title The cost of failed first-line cancer treatment related to continued smoking in Canada
 
Creator Iragorri, N.
Essue, B.
Timmings, C.
Keen, D.
Bryant, H.
Warren, G.W.
 
Subject Attributable cancer treatment failures
cost burden
smoking cessation
 
Description Background Smoking by cancer patients and survivors causes adverse cancer treatment outcomes, but little infor­mation is available about how smoking can affect cancer treatment costs.
Methods We developed a model to estimate attributable cancer treatment failure because of continued smoking after a cancer diagnosis (afs). Canadian health system data were used to determine the additional treatment cost for afs for the most common cancers in Canada.
Results Of 206,000 patients diagnosed with cancer annually, an estimated 4789 experienced afs. The annual incre­mental cost associated with treating patients experiencing afs was estimated at between $198 million and $295 million (2017 Canadian dollars), reflecting an added incremental cost of $4,810–$7,162 per patient who continued to smoke. Analyses according to disease site demonstrated higher incremental costs where the smoking prevalence and the cost of individual second-line cancer treatment were highest. Of breast, prostate, colorectal, and lung cancers, lung cancer was associated with the highest incremental cost for treatment after afs.
Conclusions The costs associated with afs in Canada after a cancer diagnosis are considerable. Populations in which the smoking prevalence and treatment costs are high are expected to benefit the most from efforts aimed at increasing smoking cessation capacity for patients newly diagnosed with cancer.
 
Publisher Multimed Inc.
 
Date 2020-08-17
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
application/pdf
text/html
 
Identifier http://www.current-oncology.com/index.php/oncology/article/view/5951
10.3747/co.27.5951
 
Source Current Oncology; Vol. 27 No. 6 (2020)
1718-7729
1198-0052
 
Language eng
 
Relation http://www.current-oncology.com/index.php/oncology/article/view/5951/9635
http://www.current-oncology.com/index.php/oncology/article/view/5951/9539
http://www.current-oncology.com/index.php/oncology/article/view/5951/9679
 
Rights Copyright (c) 2020 Current Oncology
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library